[1]唐武兵,杨 文,陈健智,等.尼妥珠单抗联合调强适形放疗及化疗治疗局部晚期肺鳞癌的研究[J].医学信息,2019,32(20):1-4.[doi:10.3969/j.issn.1006-1959.2019.20.001]
　TANG Wu-bing,YANG Wen,CHEN Jian-zhi,et al.Study of Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Lung Squamous Cell Carcinoma[J].Journal of Medical Information,2019,32(20):1-4.[doi:10.3969/j.issn.1006-1959.2019.20.001]
点击复制

尼妥珠单抗联合调强适形放疗及化疗治疗局部晚期肺鳞癌的研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年20期
页码:
1-4
栏目:
出版日期:
2019-10-15

文章信息/Info

Title:
Study of Nimotuzumab Combined with Intensity-modulated Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Lung Squamous Cell Carcinoma
文章编号:
1006-1959（2019）20-0001-04
作者:
唐武兵1; 杨 文1; 陈健智2; 潘兴喜1; 陈永发1; 伍楚蓉1; 袁燕玲1; 童丽华1
（南方医科大学附属南海医院肿瘤一科1，病理科2，广东 佛山 528200）
Author(s):
TANG Wu-bing1; YANG Wen1; CHEN Jian-zhi2; PAN Xing-xi1; CHEN Yong-fa1; WU Chu-rong1; YUAN Yan-ling1; TONG Li-hua1
(Department of Oncology,Subject One1,Department of Pathology2,Nanhai Hospital,Southern Medical University,Foshan 528200,Guangdong,China)
关键词:
非小细胞肺癌; 放射治疗; 化学治疗; 尼妥珠单抗; 靶向治疗; 表皮生长因子受体
Keywords:
Non-small cell lung cancer; Radiotherapy; Chemotherapy; Nimotuzumab; Targeted therapy;  Epidermal growth factor receptor
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2019.20.001
文献标志码:
A
摘要:
目的 探讨尼妥珠单抗联合调强适形放疗（IMRT）及化疗治疗局部晚期肺鳞癌的临床疗效。方法 选取2015年1月~2018年12月我院经组织病理确诊为肺鳞癌且免疫组织化学检查表达EGFR的Ⅲa~Ⅲb期患者58例，采用随机数字表法分为对照组（n=28）和观察组（n=30）。对照组采用IMRT及化疗治疗，观察组在对照组基础上联合尼妥珠单抗治疗，比较两组EGFR表达、近期疗效、不良反应及远期疗效。结果 两组EGFR表达比较，差异无统计学意义（P＞0.05）。观察组总有效率（ORR）高于对照组（73.33% vs 46.43%），疾病控制率（DCR）高于对照组（96.67% vs 67.86%），差异有统计学意义（P＜0.05）。两组白细胞下降、血红蛋白下降、血小板下降、胃肠道反应、肝功能异常、肾功能异常、放射性肺炎、放射性食管炎比较，差异无统计学意义（P＞0.05）。观察组无进展生存期（PFS）和总生存期（OS）较对照组延长，差异有统计学意义（P＜0.05）。结论 尼妥珠单抗联合IMRT及化疗治疗局部晚期肺鳞癌，可有效改善患者的治疗有效率和病情控制效果,且不良反应低，耐受性好，远期疗效较好。
Abstract:
Objective To investigate the efficacy of nimotuzumab combined with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced lung squamous cell carcinoma.Methods From January 2015 to December 2018, 58 patients with stage IIIa~IIIb who were diagnosed as lung squamous cell carcinoma and immunohistochemically examined for EGFR were enrolled in our hospital. The patients were randomly divided into control group (n=28)and observation group (n=30). The control group was treated with IMRT and chemotherapy. The observation group was treated with rituximab in the control group. The EGFR expression, short-term efficacy, adverse reactions and long-term efficacy were compared between the two groups.Results There was no significant difference in EGFR expression between the two groups (P>0.05). The ORR of the observation group was higher than that of the control group (73.33% vs 46.43%), and the DCR was higher than that of the control group (96.67% vs 67.86%),the difference was statistically significant (P<0.05). There were no significant differences in white blood cell decline, hemoglobin decline, thrombocytopenia, gastrointestinal reactions, liver dysfunction, renal dysfunction, radiation pneumonitis, and radiation esophagitis between the two groups (P>0.05). The PFS and OS in the observation group were longer than those in the control group,the difference was statistically significant (P<0.05).Conclusion Nimotuzumab combined with IMRT and chemotherapy for locally advanced lung squamous cell carcinoma can effectively improve the treatment efficiency and disease control effect, and has low adverse reactions, good tolerance and good long-term efficacy.

参考文献/References:

[1]Xu S,Ramos-Suzarte M,Bai X,et al.Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients:a single institute experience[J].Oncotarget,2016,7(22):33391-33407. [2]de Castro Junior G,Segalla JG,de Azevedo SJ,et al.A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer:NICE trial[J].Eur J Cancer,2018,88(1):21-30. [3]Subramanian S,Sridharan N,Balasundaram V,et al.Effectiveness and tolerability of nimotuzumab in unresectable,locally advanced/metastatic esophageal cancer:Indian hospital-based retrospective evidence[J].South Asian J Cancer,2019,8(2):112-115. [4]Chen YF,Tang WB,Pan XX,et al.Safety and efficacy of nimotuzumab combined with hemoradiotherapy in Chinese patients with locally advanced cervical cancer[J].Onco Targets Ther,2017(10):4113-4119. [5]Du XJ,Li XM,Cai LB,et al.Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma:a phase Ⅱ multicenter clinical trial[J].J Cancer,2019,10(14):3214-3223. [6]张坤宁,路军,赵宏颖,等.表皮生长因子受体、人类表皮生长因子受体2、人类表皮生长因子受体3表达与非小细胞肺癌预后的关系[J].肿瘤研究与临床,2016,28(2):73-89. [7]周际昌.实用肿瘤内科治疗(第2版)[M].北京:北京科学技术出版社,2016. [8]李晔雄.肿瘤放射治疗学(第5版)[M].北京:中国协和医科大学出版社,2018. [9]苏宁,张贤兰,黄惠怡,等.晚期肺腺癌驱动基因分布及其一线治疗现状-单中心真实世界研究[J].实用医学杂志,2019,35(4):537-540. [10]张童童,李峻岭.存在驱动基因突变肺鳞癌患者的临床病理特征及预后分析[J].中国肺癌杂志,2016,19(10):648-652. [11]Concha-Benavente F,Ferris RL.Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy[J].Frontiers in Pharmacology,2017(8):332. [12]Zhu J,Xin Y,Liu X,et al.Nimotuzumab enhances the sensitivity of non-small cell lung cancer cells to tumor necrosis factor-α by inhibiting the nuclear factor-кB signaling pathway[J].Experimental and Therapeutic Medicine,2018(5):3345-3351. [13]Garrido G,Rabasa A,Garrido C,et al.Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab[J].Front Pharmacol,2017(8):595. [14]Kato K,Ura T,Koizumi W,et al.Nimotuzumab combined with concurrent hemoradiotherapy in Japanese patients with esophageal cancer:A phase I study[J].Cancer Science,2018,109(3):785-793. [15]Peng H,Tang LL,Liu X,et al.Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma:a big-data,intelligence platform-based analysis[J].BMC Cancer,2018,18(1):323. [16]Zhao J,Zhuo M,Wang Z,et al.A phase Ⅰ study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer[J].Chinese Journal of Cancer Research,2016,28(1):12-18. [17]Li J,Yan H.Skin toxicity with anti-EGFR monoclonal antibody in cancer patients:a meta-analysis of 65 randomized controlled trials[J].Cancer Chemother Pharmacol,2018,82(4):571-583.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(20):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(20):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]许益芬.三维适型放疗与调强放疗在胸中段食管癌根治性放疗中的 剂量学比较[J].医学信息,2018,31(13):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
　XU Yi-fen.Dosimetric Comparison of Three-dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Radical Radiotherapy of Middle Thoracic Esophageal Carcinoma[J].Journal of Medical Information,2018,31(20):73.[doi:10.3969/j.issn.1006-1959.2018.13.021]
[4]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(20):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(20):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(20):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(20):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[9]刘 慧,付 雅,皈 燕,等.呼吸动度对食管癌靶区影响及呼吸运动管理策略[J].医学信息,2022,35(12):93.[doi:10.3969/j.issn.1006-1959.2022.12.022]
　LIU Hui,FU Ya,GUI Yan,et al.Effect of Respiratory Movement on Esophagus Cancer Target Volume and Respiratory Motility Management Stratege[J].Journal of Medical Information,2022,35(20):93.[doi:10.3969/j.issn.1006-1959.2022.12.022]
[10]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(20):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]

更新日期/Last Update: 2019-10-15